MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (mnc pharma)
- GSK PHARMA
GSK PHARMA Share Price (GLXO)
Here is the latest stock price and chart of GSK PHARMA. For more details, see the GSK PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
NOW LIVE: Watch Top 3 Stocks for 2022 MEGA Summit
| Live BSE Quotes | Jan 18, 2022 03:35:00 PM | ||
|---|---|---|---|
| Price (Rs)1,718.30 | Open (Rs) 1,734.55 | High (Rs) 1,750.00 | Low (Rs) 1,695.35 |
| % Change-1.14 | Volume 3,043 | Value (Rs) 5,228,787 | 52-Week H/L 1,917.00 / 1,379.00 |
| Live NSE Quotes | Jan 18, 2022 3:29:56 PM | ||
|---|---|---|---|
| Price (Rs)1,715.60 | Open (Rs) 1,738.00 | High (Rs) 1,753.35 | Low (Rs) 1,695.05 |
| % Change-1.31 | Volume 25,587 | Value (Rs) 44,133,481 | 52-Week H/L 1,918.75 / 1,376.00 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -1.14% | 1 Month -0.45% | 3 Months 16.52% | 1 Year 12.38% | 5 Years (CAGR)* 4.60% | 10 Years (CAGR)* 5.69% |
* Compound Annual Growth Rate
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 29.29 | P/E Ratio (x) 58.67 | Market Cap (Rs m) 291,090.33 | P/BV (x) 19.42 | Dividend Yield (%) 1.75 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
GSK PHARMA Share Price Today:
GSK PHARMA last traded price was down 1.1% to Rs 1,718.3 on the BSE. On the NSE, GSK PHARMA last traded price was down 1.3% to Rs 1,715.6. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 1.6%. And the benchmark S&P BSE SENSEX was at 60,754.9 (down 0.9%).
Over the last 30 days, the GSK PHARMA share price is down 7.9%. And over the last one year, GSK PHARMA share price is up 13.2%.
The current market capitalisation of GSK PHARMA stands at Rs 291,090.33 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of December 2021, company promoters held 75.00% stake in GSK PHARMA, with no shares having been pledged. To know more, check out the latest shareholding pattern of GSK PHARMA.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
Today's Market
Sensex Tanks 554 Points, Nifty Ends Near 18,100; Maruti, Tech Mahindra & Tata Consumer Plunge 4%(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Related Views On News
GSK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)
Oct 26, 2021 | Updated on Oct 26, 2021Here's an analysis of the annual report of GSK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)
Dec 16, 2021In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.
5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)
Dec 3, 2021As the new variant of Covid-19 emerges, keep an eye on these stocks.
This Stock Just Made a Historical Debut on the Exchanges (Views On News)
Nov 15, 2021Shares of the company listed at premium of 253% from its IPO price, the highest ever.
More Views on NewsMost Popular
India's Best Semiconductor Stocks 
(Views On News)
Jan 7, 2022
Modern wars are fought with semiconductors. India's best semiconductor stocks have big tailwinds from defence and manufacturing.
10 Indian Companies with the Fastest Growth in Dividend Payouts... (Views On News)
Jan 10, 2022These companies have been consistently paying higher dividends for several years.
Tata Steel vs SAIL: Which Stock is Better? (Views On News)
Jan 13, 2022With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.
Looking for Consistent Compounding Stocks? Here's a Watchlist for You (Views On News)
Jan 6, 2022These companies have generated mind boggling returns for investors over the years.
Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain (Views On News)
Jan 11, 2022The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2022
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: How to Profit from Sensex 100,000
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA - ALBERT DAVID COMPARISON
COMPARE GSK PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.